Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

Novo Nordisk (NVO) announced top-line data from the kidney outcomes study, FLOW, evaluating the efficacy of Ozempic (semaglutide) as an adjunct to standard of carefor the prevention of the progression of renal impairment in people with type II diabetes (T2D) and chronic kidney disease (CKD) compared with placebo.Per the data readout, the FLOW outcomes study achieved its primary endpoint of a superior reduction of 24% in kidney disease progression, as well as cardiovascular and kidney death for people treate ...